LBI-HTA - Publications - Search - Year: 2004
Number of items: 60.

Wild, C. (2004): [Genetic testing for predisposition]. ITA-Newsletter December 2004: 8.

Wild, C. (2004): [Rituximab (MabThera®) as treatment for non-Hodgkin's lymphoma]. HTA-Newsletter 32: 3.

Wild, C. and Antes, G. (2004): [Registration of all clinical trials]. ITA-Newsletter December 2004: 13.

Wild, C. (2004): [Communication and error management culture. Editorial]. HTA-Newsletter 32: 1.

Wild, C. (2004): [Directives for end-of-life care: Living will and health care power of attorney]. HTA-Newsletter 32: 3-4.

Wild, C. (2004): [Endometrial ablation techniques in the treatment of uterine bleeding]. HTA-Newsletter 32: 2.

Wild, C. (2004): [Breast cancer care: Quality indicators]. HTA-Newsletter 32: 4.

Wild, C. (2004): [Drug eluting stents: An economic analysis]. HTA-Newsletter 31: 3-4.

Jonas, S. (2004): [Genetic testing. Editorial]. HTA-Newsletter 31: 1.

Wild, C. (2004): [Vacuum assisted closure for treating wounds]. HTA-Newsletter 31: 2-3.

Wild, C. (2004): [Implantable defibrillators/ICD]. HTA-Newsletter 31: 2.

Wild, C. (2004): [Genetic testing for predisposition]. HTA-Newsletter 31: 4.

Wild, C. (2004): [HTAi annual meeting in Krakow]. ITA-Newsletter September 2004: 11-13.

Wild, C. (2004): [Methods of hysterectomy]. HTA-Newsletter 30: 2.

Wild, C. (2004): [Telephone triage services]. HTA-Newsletter 30: 3-4.

Wild, C. (2004): [Home-based chemotherapy: Evaluation criteria]. HTA-Newsletter 30: 4.

Wild, C. (2004): [Sclerotherapy for leg varicose veins]. HTA-Newsletter 30: 2-3.

Wild, C. (2004): [The Oregon drug class review project as initiative for generics]. ITA-Newsletter September 2004: 13.

Wild, C. and Antes, G. (2004): [Registration of all clinical trials. Editorial]. HTA-Newsletter 30: 1-2.

Wild, C. (2004): [Short acting insulin analogues in the treatment of diabetes mellitus]. HTA-Newsletter 29: 2.

Wild, C. (2004): [Prevention and therapy of Hepatitis C]. HTA-Newsletter 29: 3-4.

Wild, C. (2004): [Whole-body computed tomography as a screening test]. HTA-Newsletter 29: 2-3.

Wild, C. (2004): [New technologies in cervical cancer screening]. HTA-Newsletter 29: 4.

Perleth, M. (2004): [HTA and the evaluation of innovations. Editorial]. HTA-Newsletter 29: 1.

Felder-Puig, R. and Wild, C. (2004): Current research and funding in the EU25 countries in the area of asthma in children. Fast-track study initiated by the Joint Research Centre of the European Commission. ITA-Projektbericht 27.

Jonas, S. and Jessner, W. and Rafetseder, O. and Wild, C. (2004): [Chronic hepatitis C: Implications for therapy and economic resources in Austria]. ITA-Projektbericht 26.

Wild, C. (2004): [Liposuction in cosmetic surgery]. HTA-Newsletter 28: 2.

Wild, C. (2004): [Low-intensity pulsed ultrasound for bone healing in pseudarthrosis]. HTA-Newsletter 28: 2-3.

Wild, C. (2004): [HTA´s role in the maintenance of a health care system based on solidarity]. ITA-Newsletter June 2004: 10.

Wild, C. (2004): [Robodoc®: Robotics in surgery]. HTA-Newsletter 28: 3-4.

Wild, C. (2004): [The Oregon drug class review project as initiative for generics. Editorial]. HTA-Newsletter 28: 1.

Wild, C. (2004): [Teriparatide (Forsteo®) in the treatment of osteoporosis]. HTA-Newsletter 28: 4.

Wild, C. (2004): [Bisphosphonates: Treatment of bone metastases]. HTA-Newsletter 27: 2.

Wild, C. (2004): [CT and MR angiography. Diagnostics of renal artery stenosis]. HTA-Newsletter 27: 3-4.

Wild, C. (2004): [ERCP vs. MRCP: Diagnostics of biliary tract diseases]. HTA-Newsletter 27: 2-3.

Wild, C. (2004): [Photodynamic therapy/PDT]. HTA-Newsletter 27: 4.

Wild, C. (2004): [The myth of cancer prevention: Heresy or guidance to maturity. Editorial]. HTA-Newsletter 27: 1.

Wild, C. (2004): [Radiofrequency ablation: Therapy of liver tumours] . HTA-Newsletter 26: 4.

Wild, C. (2004): [The excimer laser: Treatment of short-sightedness]. HTA-Newsletter 26: 2.

Wild, C. (2004): [Age-related macular degeneration: An update]. HTA-Newsletter 26: 3-4.

Wild, C. (2004): [LeukoScan®: Diagnostics of osteomyelitis]. HTA-Newsletter 26: 2-3.

Wild, C. (2004): [Shared decision making. Editorial]. HTA-Newsletter 26: 1.

Wild, C. and Goldgruber, R. (2004): [Assessment of non-ionic contrast media]. ITA-Newsletter March 2004: 4.

Wild, C. (2004): [Stereotactic radiosurgery]. HTA-Newsletter 25: 4.

Wild, C. (2004): [Non-ionic contrast media]. HTA-Newsletter 25: 2.

Wild, C. (2004): [Screening for colorectal cancer in Austria]. HTA-Newsletter 25: 2-3.

Wild, C. (2004): [Transparency in the pharmaceutical industry. Editorial]. HTA-Newsletter 25: 1-2.

Wild, C. (2004): [Electrostimulation after stroke]. HTA-Newsletter 25: 3-4.

Wild, C. and Goldgruber, R. (2004): [Non-commercial clinical trials]. ITA-Newsletter March 2004: 10-11.

Wild, C. (2004): [Sentinel node biopsy (SNB) in breast cancer]. HTA-Newsletter 24: 2-3.

Wild, C. (2004): [Intraoperative radiotherapy in early stage breast cancer]. HTA-Newsletter 24: 4.

Wild, C. (2004): [Mammography screening in Austria. Editorial]. HTA-Newsletter 24: 1-2.

Wild, C. (2004): [Breast cancer diagnosis by magnetic resonance imaging or positron emission tomography (PET)]. HTA-Newsletter 24: 3-4.

Wild, C. (2004): [Epithelial cell cytology in breast cancer risk assessment]. HTA-Newsletter 24: 2.

Wild, C. (2004): [The myth of cancer prevention: Heresy or guidance to maturity]. ÖKZ: Österreichische Krankenhauszeitung 45 (4): 10-11.

Wild, C. (2004): [HTAi annual meeting in Krakow]. ZaeFQ: Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 98: 556.

Wild, C. and Jonas, S. and Rafetseder, O. (2004): [Colon cancer screening]. Mitteilungen der Sanitätsverwaltung 11: 14-15.

Wild, C. and Puig, S. (2004): [Me-too pharmaceuticals - Marketing-strategies of drug producers and drug purchasers. Example: Non-ionic contrast media]. Das Gesundheitswesen 66 (11): 716-722.

Wild, C. (2004): [HTAi annual meeting in Krakow]. ÖKZ: Österreichische Krankenhauszeitung 45 (7/8): 34-35.

Wild, C. (2004): [The Austrian health care system]. CliniCum (1-2): 54.

This list was generated on Thu Jul 20 16:00:11 2017 CEST.